CEO, Evogene
Search every verified Ofer Haviv interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Ofer Haviv, President and CEO of Evogene, described the company's business strategy and recent developments in a June 2024 company presentation. He stated that Evogene is a publicly traded company on the Tel Aviv Stock Exchange and NASDAQ. Haviv outlined the company's focus on developing life science products based on microbes, small molecules, and genetic elements, using three AI technology engines. He explained that Evogene's business strategy involves forming partnerships through licensing or collaboration with domain-specific companies to develop novel products while reducing financial and development risk. Haviv highlighted a success story involving Evogene's subsidiary, Ctera, which entered into a frame supply agreement with Eni, a major global oil and gas producer, in early 2023. Following this agreement, Ctera received purchase orders for its elite seed varieties totaling over 11 million, expected to be supplied by the end of 2024. In a 2021 interview, Haviv discussed the company's shift in business model starting in 2015, moving from helping partners develop products to developing products internally and spinning out scientist teams into separate legal entities. He also noted that Biomica, another subsidiary, identified four gut microbes (BMC128) that improved the efficacy of PD-1 checkpoint inhibitors in mouse cancer models, with plans to initiate a first-in-human clinical study.
“Evogen is a publicly traded company both on the Tel Aviv Stock Exchange and NASDAQ.”
“We were very proud when in early 2023 Ctera entered into a frame supply agreement with Eni; following the frame agreement, Ctera received purchase orders for its Elite seed varieties totaling over 11 million which are expected to be supplied by the end of 2024.”
“Starting from 2015 we built a new type of business model: instead of only helping partners develop products, we decided to develop products for Evogene itself and spin out the scientist teams into separate legal entities, where initially we hold 100% and license our technology exclusively to their specific target marke...”
“Biomica identified four gut microbes (BMC128) that, when given with PD-1 checkpoint inhibitors, significantly improved efficacy in mouse cancer models (survival rising from around 40% with the drug alone to close to 75% when mice were pretreated and dosed with BMC128), and we plan to initiate a first-in-human clinical...”
Evogene Company Presentation June 2024, by Ofer Haviv, President & CEO.
Vivienne Parry talks to Ofer Haviv, CEO Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries through the use of the broadly applicable Computational Predictive Biology (CPB) platform. For more healthcare content, visit: https://www.edisongroup.com/our-conte...
Sign in to search the full transcript archive, filter by topic, and access every quote from Ofer Haviv.